CRPC w/ Bone Metastases - Results from #240

REVIEW UroToday

Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer August 28, 2015

Radium-223 for the treatment of castration-resistant prostate cancer August 13, 2015

Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival August 13, 2015

Optimal sequence of bone target drugs in metastatic prostatic cancer August 12, 2015

Health Resource Utilization Associated with Skeletal-Related Events in Patients with Advanced Prostate Cancer: A European Subgroup Analysis from an Observational, Multinational Study August 11, 2015

Radium-223 in Bone-Metastatic Prostate Cancer: Current Data and Future Prospects August 4, 2015

Bone marrow as a metastatic niche for disseminated tumor cells from solid tumors July 26, 2015

The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer July 24, 2015

Radium-223 for the treatment of castration-resistant prostate cancer - Abstract July 3, 2015

Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: An evaluation of its safety - Abstract June 30, 2015

Prognostic factors in patients treated with radium-223: the role of skeletal tumor burden on baseline 18F-fluoride-PET/CT in predicting overall survival - Abstract June 16, 2015

Radium 223: How can we optimize this new tool for metastatic castration-resistant prostate cancer? - Abstract June 16, 2015

Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report - Abstract June 1, 2015

Bayer to highlight latest oncology research at ASCO 2015 May 26, 2015

Nursing management of patients with castration-resistant prostate cancer undergoing radium-223 dichloride treatment - Abstract May 1, 2015

Radium-223 in the treatment of osteoblastic metastases: A critical clinical review - Abstract April 27, 2015

Radium-223 and other bone-targeting radiopharmaceuticals - the translation of radiation biology into clinical practice - Abstract April 21, 2015

Real-time scintigraphic assessment of intravenous radium-223 administration for quality control - Abstract April 15, 2015

Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases - Abstract April 14, 2015

One-year postapproval clinical experience with Radium-223 dichloride in patients with metastatic castrate-resistant prostate cancer - Abstract April 10, 2015

Page 13 of 15